Perspective Therapeutics, Inc.
CATX Healthcare Medical Devices
Perspective Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $884,000.00, down 39.2% from fiscal 2024. In the quarter to June 2026, revenue fell 72.1%, EPS grew 24.1%, free cash flow fell 66.1% and total debt fell 3.57%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
Follow CATX
Perspective Therapeutics, Inc. (CATX) P/E ratio
Perspective Therapeutics, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 0.0× (October 2026) — the current reading is the highest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2024 | 0.0× | — |
| FY2023 | 0.0× | — |
| FY2022 | 0.0× | — |
| FY2021 | 0.0× | — |
| FY2020 | 0.0× | — |
| FY2019 | 0.0× | — |
| FY2018 | 0.0× | — |
| FY2017 | 0.0× | — |
| FY2016 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2026 | 0.0× | — |
| Mar 2026 | 0.0× | — |
| Dec 2025 | 0.0× | — |
| Sep 2025 | 0.0× | — |
| 41 more quarters | Free account |
Against its own ten years
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| CLPT ClearPoint Neuro, Inc. compare | n/m |
| QSI Quantum-Si Incorporated compare | n/m |
| TLSI TriSalus Life Sciences, Inc. compare | n/m |
| TMCI Treace Medical Concepts, Inc. compare | n/m |
| PROF Profound Medical compare | n/m |
| CATX Perspective Therapeutics, Inc. | n/m |
| LAB Standard BioTools Inc. compare | 2.9× |
| ELMD Electromed, Inc. compare | 20.0× |
| INFU InfuSystems Holdings, Inc. compare | 31.7× |
| Medical Devices industry median | 23.2× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)